Skip to content

Total debt at other companies

Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$328K-59.1%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$2.38M+29.5%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$113M+88.3%
Eli Lilly logo
Eli LillyLLY
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
AbbVie logo
AbbVieABBV

Other financials

Income statement

See full
Operating income-$14.9M-49.9%
Net income-$13.7M-190%
EPS (diluted)-$0.15-15.4%

Balance sheet

See full
Cash & equivalents$40.1M+702%
Total equity$240.7M+388%
Total assets$253.2M+326%

Cash flow

See full
Operating cash flow-$10.4M-25.5%
CapEx$91.0K+153%
Free cash flow-$10.5M-26.1%

Valuation

See full
Market cap$1.1B+259%
Enterprise value$1.06B+251%

Returns & leverage

See full
Return on equity-30.5%-12.5pp
Debt / equity0.0×
Current ratio19.8×+14.9×

Where this comes from

Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $834K.

The official record: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Corvus Pharmaceuticals's total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Corvus Pharmaceuticals's total debt?
Corvus Pharmaceuticals (CRVS) reported total debt of $834K in Q1 2026.
How has Corvus Pharmaceuticals's total debt changed year-over-year?
Corvus Pharmaceuticals's total debt decreased by 27.7% year-over-year, from $1.15M to $834K.
What is the long-term trend for Corvus Pharmaceuticals's total debt?
Over 5 years (2020 to 2025), Corvus Pharmaceuticals's total debt has grown at a -16.5% compound annual growth rate (CAGR), from $2.31M to $937K.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.